Preparation and evaluation of arsenic trioxide glioma targeting drug delivery system loaded by PAMAM dendrimers co-modified with RGDyC and PEG.
10.19540/j.cnki.cjcmm.20180117.010
- Author:
An-Hao HUANG
1
;
Shun-Ping HAN
1
;
Yan-Ping LU
1
;
Rui MA
1
;
Hang-Sheng ZHENG
1
;
Fan-Zhu LI
1
Author Information
1. College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 311400, China.
- Publication Type:Journal Article
- Keywords:
PAMAM;
RGDyC;
arsenic trioxide;
blood brain barrier;
glioma;
polyethylene glycol
- From:
China Journal of Chinese Materia Medica
2018;43(8):1618-1625
- CountryChina
- Language:Chinese
-
Abstract:
Arsenic trioxide (ATO) is an effective component of traditional Chinese medicine arsenic. The existing studies have shown its good inhibition and apoptosis ability on a variety of tumours. However, its toxicity and difficulties in the permeability into the blood brain barrier (BBB) has the limitation in the application of glioma treatment. Polyamide-amine dendrimer (PAMAM) is a synthetic polymer with many advantages, such as a good permeability, stability and biocompatibility. Additionally, the 5th generation of PAMAM is an ideal drug carrier due to its three-dimensional structure. In this study, the 5th generation of PAMAM co-modified with RGDyC and PEG, then confirmed by ¹H-NMR. The average particle size of nanoparticles was about 20 nm according to the nanoparticle size-potential analyser and transmission electron microscopy. release showed that the nanocarrier not only has the sustained release effect, but also some pH-sensitive properties. The cell results showed that PAMAM co-modified with RGDyC and PEGAM has a lower cytotoxicity than the non-modified group . Accordingly, the drug delivery system has a better anti-tumour effect across the blood brain barrier (BBB) , which further proves the tumour targeting of RGDyC.
